Skin and Soft Tissue Infections - Pipeline Review, with Focus on Companies and Drugs – H2 2017

Published on : Aug 03, 2017

Albany, New York, August 3, 2017: The growing proportion of skin and soft tissue infection has initiated the demand for its curable drugs all across the globe. The main infection includes injury to the skin, radiation therapy, accumulation of fluid (edema) due to poor circulation, and heart failure. To cure or diagnose this infection, a pipeline review is added by Market Research Hub (MRH), titled as “Skin and Soft Tissue Infections - Pipeline Review, H2 2017” to its vast report repository. It provides an overview of the skin and soft tissue infections (Dermatology) pipeline landscape by various drugs and key players involved in the therapeutic development.

Skin and soft tissue infections involves the infection of the layers of skin and the soft tissues beneath it. The bacteria, viruses, and fungi are the main cause of the infections, by entering the body at a spot where a cut, scrape, bite, or any another wound that has broken the skin. The symptoms of the infection include warmth, swelling, and redness in a distinct area of skin, abscesses, furuncles, and carbuncles. It has various other infections such as liver disease, or past surgery to remove lymph nodes, being overweight and chronic skin conditions, such as eczema. Diagnosing the rigorous symptom and cure of the disease is critical for successful management of the soft tissue infection. The detailed pipeline review procures strategically important competitor information, analysis, and insights to formulate effective R&D strategies. It further helps in recognizing emerging players with the potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

The provided pipeline review commences with skin and soft tissue infections overview followed by its therapeutic development, assessment, and companies involved in therapeutic development. The therapeutic development explains the pipeline by companies and products to enlighten the readers. Further, the therapeutic assessment is completed by the target, mechanism of action, route of administration and molecule type. Companies listed in the report which are involved in the therapeutic development of the skin and soft tissue infection are Atox Bio Ltd., CorMedix Inc., Takeda Pharmaceutical Company Ltd., Valevia UK Ltd. and Wockhardt Ltd.

The report further profiles the infection drugs along with their product description, mechanism of action and R&D progress. Various drugs featured in the study include ADEP-4, alalevonadifloxacin, ceftaroline fosamil, CRMD-004, KBP-7072, reltecimod sodium, the small molecule for skin and soft tissue infections, and VAL-301. The report finally concludes with the featured dormant & discontinued projects by the pipeline companies followed by latest news and press releases, which helps in early and valid decision making by the industry experts.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top